Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
暂无分享,去创建一个
Marleen Keyaerts | Nick Devoogdt | David Escors | Karine Breckpot | Adrian Liston | Geert Raes | A. Liston | N. Devoogdt | Q. Lecocq | K. Breckpot | M. Keyaerts | D. Escors | G. Raes | K. Broos | Katrijn Broos | Quentin Lecocq | Dries Renmans | Tham Nguyen | D. Renmans | T. Nguyen
[1] C. Heirman,et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells , 2013, Gene Therapy.
[2] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[3] N. Devoogdt,et al. Site-specific labeling of his-tagged Nanobodies with ⁹⁹mTc: a practical guide. , 2012, Methods in molecular biology.
[4] M. Bartholomä,et al. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers , 2016, Theranostics.
[5] Rubel Chakravarty,et al. Nanobody: The “Magic Bullet” for Molecular Imaging? , 2014, Theranostics.
[6] George Sgouros,et al. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. , 2016, Cancer research.
[7] Jakub Toczek,et al. Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.
[8] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[9] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Muyldermans,et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies , 2014, Leukemia.
[11] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[12] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[13] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[14] Martin G Pomper,et al. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. , 2013, Current topics in medicinal chemistry.
[15] T. Okazaki,et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4 , 2005, Nature Immunology.
[16] C. Heirman,et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity , 2014, Oncotarget.
[17] I. Weissman,et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.
[18] Nick Devoogdt,et al. Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] S. Muyldermans,et al. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target , 2013, Expert opinion on biological therapy.
[20] Wojciech G. Lesniak,et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors , 2016, Oncotarget.
[21] R. Davis,et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[22] S. Gambhir,et al. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. , 2015, Bioconjugate chemistry.
[23] Sanjiv Sam Gambhir,et al. AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.
[24] W. Oyen,et al. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. , 2015, Cancer research.
[25] N. Devoogdt,et al. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. , 2013, Nuclear medicine and biology.
[26] Antoni Ribas,et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.
[27] J. Aerts,et al. Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation , 2014 .
[28] Michel Defrise,et al. Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[29] M. Dullaers,et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy , 2003, The journal of gene medicine.
[30] J. Frère,et al. β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae , 2001, Antimicrobial Agents and Chemotherapy.
[31] G. Freeman,et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. , 2002, Immunology letters.
[32] P. Coulie,et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.
[33] Sanjiv S Gambhir,et al. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging , 2017, The Journal of Nuclear Medicine.
[34] S. Charlton,et al. Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action , 2015, Molecular Pharmacology.
[35] Clare L. Bennett,et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells , 2011, EMBO molecular medicine.
[36] G. Freeman,et al. Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis , 2003, European journal of immunology.
[37] Serge Muyldermans,et al. Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.
[38] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[39] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[40] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[41] Jason B. Williams,et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.
[42] P. De Baetselier,et al. SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis , 2013, The Journal of Nuclear Medicine.
[43] P. De Baetselier,et al. Targeting of Human Antigen-Presenting Cell Subsets , 2013, Journal of Virology.
[44] G. Coukos,et al. Deciphering and reversing tumor immune suppression. , 2013, Immunity.
[45] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[46] Baosheng Li,et al. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions , 2019, Journal of cancer research and therapeutics.
[47] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[48] M. Azuma,et al. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. , 2015, Oral oncology.
[49] C. Vanhove,et al. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma , 2016, The Journal of Nuclear Medicine.
[50] S. Muyldermans,et al. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. , 2014, Contrast media & molecular imaging.
[51] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[52] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[53] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[54] Jinming Yu,et al. PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.
[55] M. Ridder,et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy , 2014, Oncoimmunology.
[56] L. Gordon,et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] David C. Smith,et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] G. Freeman,et al. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.
[59] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.